Artal Group S.A.

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 13, 2024), Artal Group S.A. reported 2 stock positions worth $2.4 billion. Its top holding was Cava (CAVA) at 91.0% of the portfolio, followed by Lexicon Pharmaceuticals (LXRX, 9.0%). Compared with Q2 2024, it sold out of 106 and reduced 2. The biggest sale was an exit from Scholar Rock (SRRK).

Most Recent 13F
Q2 2026
Location
LUXEMBOURG, N4
CIK
0001053906
Portfolio Value
$2.4B (Q3 2024)
SEC Filing
0001053906-24-000012 ↗ filed Nov 13, 2024

Holdings Value

0$1.0B$2.0B$3.0B$4.0B Q1 2024: $3.9B Q1 2024 Q2 2024: $3.9B Q2 2024 Q3 2024: $2.4B $2.4B Q3 2024 Q4 2024: $1.2B Q4 2024 Q1 2025: $884.2M Q1 2025 Q2 2025: $930.2M Q2 2025 Q3 2025: $758.2M Q3 2025 Q4 2025: $714.6M Q4 2025 Q1 2026: $1.0B Q1 2026 Q2 2026: $931.1M Q2 2026

Holdings 2 stocks · $2.4B
CAVA Cava Group Inc. 91.02% 17,507,990 $2.2B Reduce -25.5%
LXRX Lexicon Pharmaceuticals Inc. 8.98% 136,180,481 $213.8M Reduce -22.2%

Portfolio Sells Q2 2024 → Q3 2024
SRRK Scholar Rock Holding Corp. Sold out 0.00% −2.41
KYMR Kymera Therapeutics Inc. Sold out 0.00% −2.30
MORF Morphic Holding Inc. Sold out 0.00% −2.21
ARWR Arrowhead Pharmaceuticals Inc. Sold out 0.00% −2.13
APLS Apellis Pharmaceuticals Inc. Sold out 0.00% −1.44
DYN Dyne Therapeutics Inc. Sold out 0.00% −1.37
SLN Silence Therapeutics PLC-ADR Sold out 0.00% −1.36
SWTX Springworks Therapeutics Inc. Sold out 0.00% −1.27
CRNX Crinetics Pharmaceuticals Inc. Sold out 0.00% −1.23
MRUS Merus NV Sold out 0.00% −1.16
ONC Beone Medicines Ltd.-ADR Sold out 0.00% −1.11
RVMD Revolution Medicines Inc. Sold out 0.00% −1.01
KURA Kura Oncology Inc. Sold out 0.00% −0.96
VERA Vera Therapeutics Inc. Sold out 0.00% −0.85
NMRA Neumora Therapeutics Inc. Sold out 0.00% −0.71
CYTK Cytokinetics Inc. Sold out 0.00% −0.69
RNAM Avidity Biosciences Inc. Sold out 0.00% −0.69
IGMS Igm Biosciences Inc. Sold out 0.00% −0.59
WVE Wave Life Sciences Ltd. Sold out 0.00% −0.58
ERAS Erasca Inc. Sold out 0.00% −0.58
TNGX Tango Therapeutics Inc. Sold out 0.00% −0.56
PRTA Prothena Corp. PLC Sold out 0.00% −0.53
CNTA Centessa Pharmaceuticals Ltd. Sold out 0.00% −0.49
CGEM Cullinan Therapeutics Inc. Sold out 0.00% −0.47
NAMS Newamsterdam Pharma Co. NV Sold out 0.00% −0.39
XENE Xenon Pharmaceuticals Inc. Sold out 0.00% −0.38
EWTX Edgewise Therapeutics Inc. Sold out 0.00% −0.38
SLDB Solid Biosciences Inc. Sold out 0.00% −0.36
KRRO Korro Bio Inc. Sold out 0.00% −0.36
ASND Ascendis Pharma A/S Sold out 0.00% −0.35
AGEN Agenus Inc. Sold out 0.00% −0.33
SYRS Syros Pharmaceuticals Inc. Sold out 0.00% −0.33
GOSS Gossamer Bio Inc. Sold out 0.00% −0.31
DNLI Denali Therapeutics Inc. Sold out 0.00% −0.30
RARE Ultragenyx Pharmaceutical Inc. Sold out 0.00% −0.29
BHVN Biohaven Ltd. Sold out 0.00% −0.27
TSHA Taysha Gene Therapies Inc. Sold out 0.00% −0.25
LXEO Lexeo Therapeutics Inc. Sold out 0.00% −0.25
SLRN Acelyrin Inc. Sold out 0.00% −0.23
JANX Janux Therapeutics Inc. Sold out 0.00% −0.22
RNAC Cartesian Therapeutics Inc. Sold out 0.00% −0.21
RAPP Rapport Therapeutics Inc. Sold out 0.00% −0.21
IOVA Iovance Biotherapeutics Inc. Sold out 0.00% −0.21
GBIO Generation Bio Co. Sold out 0.00% −0.20
SEER Seer Inc. Sold out 0.00% −0.20
VIGL Vigil Neuroscience Inc. Sold out 0.00% −0.19
MIND MEDICINE MINDMED INC Sold out 0.00% −0.19
SE Sea Ltd.-ADR Sold out 0.00% −0.18
PDD PDD Holdings Inc. Sold out 0.00% −0.16
NVDA Nvidia Corp. Sold out 0.00% −0.14

Portfolio Buys Q2 2024 → Q3 2024
None this quarter.

Options Activity Q2 2024 → Q3 2024
ARWR Arrowhead Pharmaceuticals Inc. call Sold out 1,000,000 $26.0Mbefore exit
PYPL PayPal Holdings Inc. call Sold out 26,000 $1.5Mbefore exit
GOSS Gossamer Bio Inc. call Sold out 207,000 $186Kbefore exit

Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.

Notes & Other Activity Q2 2024 → Q3 2024
PERCEPTION CAPITAL CORP III *W EXP 99/99/999 Sold out 126,666 $4Kbefore exit

Bonds, preferreds, convertibles and warrants; not part of the stock holdings or percentages above.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 2$931.1MCAVA, LXRX
Q1 2026 2$1.0BCAVA, LXRX
Q4 2025 2$714.6MCAVA, LXRX
Q3 2025 2$758.2MCAVA, LXRX
Q2 2025 2$930.2MCAVA, LXRX
Q1 2025 2$884.2MCAVA, LXRX
Q4 2024 2$1.2BCAVA, LXRX
Q3 2024 2$2.4BCAVA, LXRX
Q2 2024 108$3.9BCAVA, LXRX, SRRK, KYMR, MORF
Q1 2024Amended 107$3.9BCAVA, LXRX, SRRK, KYMR, ARWR